Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,564.47
-8.3350-0.53%
Number of Gainers:1
Number of Losers:6
Number of Flat:- -
PE:- -
High:1,591.44
Open:1,573.14
Low:1,558.99
Close:1,572.81
Volume:60.44M
Turnover:4.79B
Market Cap:1.63T
Float Cap:1.57T

Loading ...

Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup

TIPRANKS
·
Yesterday

Novo Nordisk is Dropping Some Weight. it Still Faces a Bigger Challenge.

Dow Jones
·
Yesterday

Eli Lilly Exec Says Co NOW Has More than 30% Share in New Starts Within Oral Obesity Treatment Market -Morgan Stanley Conf

THOMSON REUTERS
·
Yesterday

Amgen’s Phase 3 Dazodalibep Study Nears Data Spotlight for Sjögren’s Investors

TIPRANKS
·
Yesterday

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
Yesterday

Novo Nordisk A/S Series B Stock Rises Monday, Outperforms Market

Dow Jones
·
Yesterday

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

Novo Nordisk Kept at Hold as Analyst Maintains $47 Price Target Amid Strategic Uncertainty

TIPRANKS
·
Sep 14

Roche, GSK's Lung-Cancer Drug Candidates Show Promise in China

Dow Jones
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

Data Retention Terms Prompt Restraints on AI Model Use for Sensitive Operations

Deep News
·
Sep 14

FDA Approves Shorter Monitoring Time for Amgen’s Imdelltra First Two Doses

Reuters
·
Sep 14

Amgen - Imdelltra Monitoring Reduced to 6-8 Hours for First Two Infusions

THOMSON REUTERS
·
Sep 14

Amgen - Imdelltra Monitoring Remains 6-8 Hours for Third Dose, 3-4 Hours for Cycles 3-4

THOMSON REUTERS
·
Sep 14

FDA Approves Reduced Monitoring Time for First Two Doses of Imdelltra®

THOMSON REUTERS
·
Sep 14

Amgen - Patients to Receive Follow-up Assessment After First Two Imdelltra Doses

THOMSON REUTERS
·
Sep 14

Novo Signals New Direction of Travel with Rebrand

Dow Jones
·
Sep 14

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

GlobeNewswire
·
Sep 14

One State's Battle to Stop People from Taking Unapproved Weight-Loss Drugs

Dow Jones
·
Sep 14

Sino Biopharmaceutical Stock Advances 4.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 14